Cytogenetic details and treatment response of the 21 patients with clonal ACAs
Patient . | Sex . | Karyotype at diagnosis (% metaphases with ACAs) . | Der(9) deletion . | CgR 12m . | Outcome . |
---|---|---|---|---|---|
1 | Male | 45,X,-Y,t(9;22)(q34;q11) (65) | Yes | CCgR | CCgR |
2 | Male | 45,X,-Y,t(9;22)(q34;q11) (100) | No | CCgR | CCgR |
3 | Male | 45,X,-Y,t(9;22)(q34;q11) (100) | No | CCgR | CCgR |
4 | Male | 45,X,-Y,t(9;22)(q34;q11) (100) | No | NoCgR | Death |
5 | Male | 45,X,-Y,t(9;22)(q34;q11) (100) | No | CCgR | CCgR |
6 | Male | 45,X,-Y,t(9;22)(q34;q11) (100) | No | NE | Failure |
7 | Male | 45,X,-Y,t(9;22)(q34;q11) (100) | Yes | PCgR | CCgR |
8 | Male | 45,X,-Y,t(9;22)(q34;q11) (33) | No | CCgR | CCgR |
9 | Male | 45,X,-Y,t(9;22)(q34;q11) (100) | No | PCgR | CCgR |
10 | Male | 47,XY,+8,t(9;22)(q34;q11) (14) | No | mCgR | Death |
11 | Male | 47,XY,+8,t(9;22)(q34;q11) (100) | No | PCgR | Failure |
12 | Male | 47,XY,+8,t(9;22)(q34;q11) (100) | No | CCgR | CCgR |
13 | Male | 47,XY,t(9;22)(q34;q11),+19 (100) | No | PCgR | Drop-out |
14 | Male | 47,XY,t(9;22)(q34;q11),+19 (100) | No | CCgR | Failure |
15 | Male | 46,XY,t(9;22)(q34;q11),del(20)(q11q13) (100) | Yes | CCgR | CCgR |
16 | Male | 46,XY,del(7)(p21),t(9;22)(q34;q11) (100) | No | NE | Failure |
17 | Female | 46,XX,t(1;7)(p36;q31),t(9;22)(q34;q11) (100) | No | CCgR | CCgR |
18 | Male | 46,XY,t(6;11)(q13;q13)t(9;22)(q34;q11) (100) | No | CCgR | CCgR |
19 | Female | 46,XX,t(7;19)(q21;p13),t(9;22;22)(q34;q11;q11) (100) | No | CCgR | CCgR |
20 | Male | 46,XY,t(9;22)(q34;q11),t(X;13)(q13;q32) (100) | Yes | CCgR | Failure |
21 | Female | 46,XX,t(2;14)(p13;q32),der(14)t(2;14)(p13;q32), t(9;22)(q34;q11) (100) | No | NE | Failure |
Patient . | Sex . | Karyotype at diagnosis (% metaphases with ACAs) . | Der(9) deletion . | CgR 12m . | Outcome . |
---|---|---|---|---|---|
1 | Male | 45,X,-Y,t(9;22)(q34;q11) (65) | Yes | CCgR | CCgR |
2 | Male | 45,X,-Y,t(9;22)(q34;q11) (100) | No | CCgR | CCgR |
3 | Male | 45,X,-Y,t(9;22)(q34;q11) (100) | No | CCgR | CCgR |
4 | Male | 45,X,-Y,t(9;22)(q34;q11) (100) | No | NoCgR | Death |
5 | Male | 45,X,-Y,t(9;22)(q34;q11) (100) | No | CCgR | CCgR |
6 | Male | 45,X,-Y,t(9;22)(q34;q11) (100) | No | NE | Failure |
7 | Male | 45,X,-Y,t(9;22)(q34;q11) (100) | Yes | PCgR | CCgR |
8 | Male | 45,X,-Y,t(9;22)(q34;q11) (33) | No | CCgR | CCgR |
9 | Male | 45,X,-Y,t(9;22)(q34;q11) (100) | No | PCgR | CCgR |
10 | Male | 47,XY,+8,t(9;22)(q34;q11) (14) | No | mCgR | Death |
11 | Male | 47,XY,+8,t(9;22)(q34;q11) (100) | No | PCgR | Failure |
12 | Male | 47,XY,+8,t(9;22)(q34;q11) (100) | No | CCgR | CCgR |
13 | Male | 47,XY,t(9;22)(q34;q11),+19 (100) | No | PCgR | Drop-out |
14 | Male | 47,XY,t(9;22)(q34;q11),+19 (100) | No | CCgR | Failure |
15 | Male | 46,XY,t(9;22)(q34;q11),del(20)(q11q13) (100) | Yes | CCgR | CCgR |
16 | Male | 46,XY,del(7)(p21),t(9;22)(q34;q11) (100) | No | NE | Failure |
17 | Female | 46,XX,t(1;7)(p36;q31),t(9;22)(q34;q11) (100) | No | CCgR | CCgR |
18 | Male | 46,XY,t(6;11)(q13;q13)t(9;22)(q34;q11) (100) | No | CCgR | CCgR |
19 | Female | 46,XX,t(7;19)(q21;p13),t(9;22;22)(q34;q11;q11) (100) | No | CCgR | CCgR |
20 | Male | 46,XY,t(9;22)(q34;q11),t(X;13)(q13;q32) (100) | Yes | CCgR | Failure |
21 | Female | 46,XX,t(2;14)(p13;q32),der(14)t(2;14)(p13;q32), t(9;22)(q34;q11) (100) | No | NE | Failure |
PCgR indicates partial CgR; mCgR, minor CgR, NE, not evaluable; Failure, according to 2009 European LeukemiaNet criteria, described under “Definition of progression, failure, abd events”; and Drop-out, imatinib permanent discontinuation for any reason different from failure.